Enantioselective Dearomatizing Formal (3+3) Cycloadditions of Bicyclobutanes with Aromatic Azomethine Imines: Access to Fused 2,3-Diazabicyclo[3.1.1]heptanes

Xue-Chun Yang,[‡[a]] Feng Wu,[‡[a]] Wen-Biao Wu,[‡[a]] Xu Zhang,[[b]] and Jian-Jun Feng[*[a]]

Dedicated to Professor Yong Tang and Wanbin Zhang on the occasion of his 60th birthday

[a] X.-C. Yang,[‡] F. Wu,[‡] Dr. W.-B. Wu,[‡] Prof. Dr. J.-J. Feng
State Key Laboratory of Chemo/Biosensing and Chemometrics, Advanced Catalytic Engineering Research Center of the Ministry of Education, College of Chemistry and Chemical Engineering, Hunan University
Changsha, Hunan 410082, P. R. China
E-mail: jianjunfeng@hnu.edu.cn
[b] X. Zhang
School of Chemistry & Chemical Engineering, Yangzhou University, Yangzhou, 225002, P.R. China
[‡] These authors contributed equally to this work.

Supporting information for this article is given via a link at the end of the document.

Abstract: Although cycloadditions of bicyclobutanes (BCBs) have emerged as a reliable approach for producing bicyclo[n.1.1]alkanes such as azabicyclo[3.1.1]heptanes (aza-BCHeps), serving as saturated bioisosteres of arenes, the catalytic asymmetric variant remains underdeveloped and presents challenges. Herein, we developed several Lewis acid-catalyzed systems for the challenging dearomatizing (3+3) cycloaddition of BCBs and aromatic azomethine imines. This resulted in fused 2,3-diazabicyclo[3.1.1]heptanes, introducing a novel chemical space for the caged hydrocarbons. Moreover, an asymmetric Lewis acid catalysis strategy was devised for the (3+3) cycloadditions of BCBs and *N*-iminoisoquinolinium ylides, forming chiral diaza-BCHeps with up to 99% yield and 97% *ee*. This work represents the first successful demonstration of asymmetric (3+3) cycloaddition by introducing a chiral environment through the activation of BCBs.

Nitrogen heterocycles are ubiquitously present in nature and represent crucial structural elements in pharmaceuticals.[1] Njardarson's analysis of FDA-approved small-molecule drugs from 2013 to 2023 shows that 82% of the newly approved small-molecule drugs in this period contain a nitrogen heterocycles. Six-membered non-aromatic *N*-heterocycles are the most prevalent, followed by fused *N*-heterocycles, in the approved new drugs.[1b] Besides fused *N*-heterocycles, bridged bicyclic nitrogen heterocycles like diazabicyclo[3.2.1]octane and tropane derivatives belong to the top 35 most frequently appearing *N*-heterocyclic compounds.[1] Therefore, developing atom-economical and particularly catalytic asymmetric strategies to construct the aforementioned *N*-heterocyclic scaffolds is crucial for diverse applications, including drug discovery (Scheme 1A).

Aromatic azomethine imines are versatile and easily synthesized compounds employed as substrates in dipolar (3+3) cycloadditions to produce valuable hydroisoquinoline and related six-membered *N*-heterocycle frameworks.[2] These structures serve as core components in numerous natural products and pharmaceuticals.[3] In 2008, the Charette group pioneered the Lewis acid-catalyzed non-asymmetric (3+3) cycloadditions of 1,1-cyclopropane diesters with *N*-iminoquinolinium and *N*-iminoisoquinolinium ylides.[4a] Tang's group later successfully developed the asymmetric version of the aforementioned (3+3) reaction.[4b] A crucial element contributing to their success was the utilization of a carefully designed trisoxazoline (TOX)-nickel catalyst to create a stable chiral environment by coordinating with two chelating, electron-withdrawing groups on cyclopropanes (Scheme 1B).[5] Up to now, there have been five literature reports on asymmetric (3+3) cycloadditions with aromatic azomethine imines.[6] However, these reports are mainly focused on constructing fused six-membered *N*-heterocycles. Cycloaddition reactions using these versatile 1,3-dipoles to form bridged bicyclic nitrogen heterocycles, especially enantioenriched bridged bicyclic cycloadducts, have not been reported yet.

Recently, bicyclo[3.1.1]heptanes (BCHeps) and aza-BCHeps have attracted increasing attention from chemists and medicinal chemists for serving as bioisosteres of *meta*-substituted benzenes and pyridines, respectively.[7] Significantly, Mykhailiuk's studies show that heteroatom (*N*- or *O*-) incorporated analogs of caged hydrocarbons (bicyclo[2.1.1]hexanes (BCHs)[8] and BCHeps) often demonstrate enhanced water solubility, improved metabolic stability, and reduced lipophilicity.[7d, 9] In this context, the (3+3) cycloadditions of bicyclobutanes (BCBs)[10] has emerged as a vital synthetic platform for building BCHeps and hetero-BCHeps skeletons, owing to the pioneering scientific contributions of Molander,[11] Waser,[12] Li,[13] Wang,[14] Zheng,[15] Deng,[16] Glorius[17] and our group.[18] Several strategies, including photocycloaddition,[11-12] pyridine-boryl radical catalysis,[13-14] Ti-catalyzed radical-relay process,[15] Lewis acid catalysis,[16,18] and silver-promoted tandem (3+3)/(3+2)/retro-(3+2) cycloaddition,[17]



Scheme 1. Outline of this work.

have been developed for efficient (3+3) cycloadditions of BCBs (Scheme 1C). Despite significant progress, the access to enantioenriched (hetero)BCHeps through catalytic asymmetric cycloadditions of BCBs remains limited and presents a persistently challenging. Very recently, our group developed the first asymmetric (3+3) cycloadditions of BCBs with vinyl oxiranes using palladium catalysis.[19] The Li group pioneered the synthesis of enantioenriched 3-aza-BCHeps through copper-catalyzed cycloadditions of BCBs with azomethine ylides.[20] The strategies employed by both groups focus exclusively on creating a stable chiral environment by activating the "X" component in the (3+X) reaction of BCBs (Scheme 1D).

Based on our interest in BCB chemistry,[21] we envisioned that the asymmetric (3+3) cycloaddition of BCBs with aromatic azomethine imines might serve as a new approach to enantiomerically enriched fused 2,3-diazabicyclo[3.1.1]heptanes (*N*,*N*-BCHeps) through a chiral Lewis acid catalyst via activating the BCBs (Scheme 1E).[22] However, this hypothesis encountered significant challenges. (a) For instance, although Deng's group has successfully established the non-asymmetric (3+3) cycloadditions of BCBs with nitrones,[16] the analogous reaction with aromatic azomethine imines remains unexplored because an energy barrier exists in the cycloaddition process, requiring dearomatization with aromatic azomethine imines.[23] (b) Achieving enantioselective control in the cycloaddition of BCBs with a single electron-withdrawing group, as opposed to donor-acceptor cyclopropanes containing two chelating, electron-withdrawing groups,[4] poses greater challenges in establishing chiral environments by forming a chiral catalyst-substrate complex with varying conformations. (c) Another key challenge in the Lewis acid catalyzed asymmetric (3+3) version is identifying

Table 1. Optimization of the reaction conditions.[a]



entry	Variation	yield (%)[b]
1	None	>99
2	toluene instead of MeCN	25
3	EtOAc instead of MeCN	23
4	1,4-dioxane instead of MeCN	22
5	DCE instead of MeCN	63
6	CH_2Cl_2 instead of MeCN	35
7[c]	$Sc(OTf)_3$ instead of $Ni(OTf)_2$	25
8[c]	$Fe(OTf)_2$ instead of $Ni(OTf)_2$	30
9[c]	$Zn(OTf)_2$ instead of $Ni(OTf)_2$	20
10[c]	$Co(OTf)_2$ instead of $Ni(OTf)_2$	33
11[c]	$BF_3{\cdot}Et_2O$ instead of $Ni(OTf)_2$	0

[a] Conditions A: **1a** (1.0 equiv), **2a** (1.2 equiv), $Ni(OTf)_2$ (10 mol%) in CH_3CN (0.05 M) at room temperature for 16 h. [b] NMR yield with CH_2Br_2 as an internal standard. [c] Performed in CH_2Cl_2.

optimal chiral catalyst that can overcome the strong racemic background reaction, thereby enabling the simultaneous construction of two congested quaternary centers and a chiral aza-trisubstituted carbon center with excellent *ee* values.[24]

Our study commences by exploring the non-asymmetric cycloadditions of Glorius's BCB **1a**[25] with isoquinoline azomethine imine **2a**. After screening of various reaction parameters, we found that the desired (3+3) reaction occurred with $Ni(OTf)_2$ as the catalyst in acetonitrile at room temperature (conditions A); the *N*,*N*-BCHep **3aa** was obtained in almost quantitative yield (Table 1, entry 1). Control experiments revealed that the solvent had substantial effect on the yield but no improvement over acetonitrile was seen (entries 2-6). Although other metal Lewis acids can produce the desired product with reduced yield (entries 7-10), main-group Lewis acids like BF_3 did not yield **3aa** (entry 11). Condition-based sensitivity screening was performed,[26] revealing that low temperature inhibited the reaction. The reaction showed moderate sensitivity to moisture, with concentration, scale, catalyst loading, high temperature, and O_2 level having no significant impact on the reaction (Table 1).

With the optimized conditions in hand, we investigated the BCB scope (Scheme 2, top). Different substituents at the phenyl moiety, such as methoxy group, halides and CF_3 group were well tolerated (**3aa**-**fa**, 70-99% yield). As a trend, electron-rich**1b** afforded relatively better results than electron deficient **1c** and **1e**. During our investigation of BCB ketones under conditions A, we discovered that a (3+3) cycloadduct **3ga** was obtained with a 9% NMR yield. To our delight, the excellent yield (99% yield of **3ga**) was achieved in CH_3CN at 50°C using $Sc(OTf)_3$ as the catalyst (conditions B, see Table S2 in ESI).

The substrate scope of BCBs containing benzoyl groups was subsequently explored under conditions B (Scheme 2, middle).



Scheme 2. Substrate scope investigation.[a-d] [a] Conditions A: **1a-f** (0.2 mmol), **2a** (0.24 mmol), $Ni(OTf)_2$ (10 mol%) in CH_3CN (4 mL) at room temperature for 16 h. [b] Conditions B: **1g-o** (0.2 mmol), **2a** (0.24 mmol), $Sc(OTf)_3$ (10 mol%) in CH_3CN (4 mL) at 50 °C for 16 h. [c] Conditions C: **1p-w** (0.2 mmol), **2a-p** (0.24 mmol), $Fe(OTf)_2$ (10 mol%) in CH_2Cl_2 (4 mL) at room temperature for 12 h. [d] Isolated yield. [e] Run at 40 °C.

The steric and electronic properties of *para*-substituents on the phenyl group of BCBs had minor impact on the yields (**3ga**-**3ka**, 81-99% yield). BCBs with substituents at the *meta*-position of the phenyl group were well-tolerated (**3la**-**ma**). Besides phenyl ketones, naphthyl (**3na**) and heteroaryl ketones (**3oa**) were also suitable for this (3+3) reaction, yielding the corresponding *N*,*N*-BCHeps in moderate to excellent yield. Additionally, we further investigated the scope of substrates containing BCBs with an acyl imidazole group by employing the $Fe(OTf)_2$ catalyst (conditions C, Scheme 2, bottom). BCBs **1p**–**1v** featuring various substituted phenyl rings (*p*-Me, *p*-OCF_3, *p*-Br, *p*-F, *p*-CF_3, *m*-Cl) furnished the corresponding cycloadducts (**3pa**–**va**) in very high yields (64–99%). Naphthyl-substituted BCB **1w** also reacted smoothly. Of note, in contrast to Glorius's observation that a BCB with a strong electron-withdrawing trifluoromethyl group on the phenyl ring resulted in a poor yield of the product,[25] our study indicates that the electronic properties of substituents on the phenyl group had minimal influence on the yields, suggesting that a benzylic carbocation intermediate may not be involved in our catalytic system.

We then evaluated the compatibility of aromatic azomethine imines **2** bearing various benzoyl protecting groups. The benzoyl protecting group of *N*-iminoisoquinolinium ylides exhibited good tolerance towards both electron-withdrawing and electron-

donating substituents (R^1), with the exception of **2e**. Azomethine imine **2f** with a thiophene-2-carbonyl group was well tolerated. Furthermore, the current (3+3) protocol is amenable to a series of azomethine imines **2** bearing different R^2 substituents, including alkyl (**3pg** and **3pj**), OMe (**3ph-pi**, **3pm**) and halogen (**3pk-pl** and **3pn-po**)[27] groups at the C3 and C5-C8 positions of isoquinoline moieties, and led to the corresponding polysubstituted *N*,*N*-BCHeps in good yield (47-99%). Gratifyingly, the reaction was not limited to *N*-iminoisoquinolinium ylides. An *N*-benzoyl iminoquinolinium ylide **2p** was successfully employed in the reaction, resulting in the formation of **4pp** with a yield of 87%.

After establishing the non-asymmetric (3+3) cycloadditions of BCBs with aromatic azomethine imines, we proceeded to develop the asymmetric (3+3) version. BCB **1p** containing bidentate chelating groups and **2b** with 4-(trifluoromethyl)benzoyl-protecting group were selected as the model substrates. In the presence of $Co(OTf)_2$ and **L1**, a 6% *ee* was detected (Table 2, entry 1), prompting us to explore different oxazoline-based

Table 2. Optimization of the asymmetric (3+3) reaction conditions.[a]



entry	Lewis acid	ligand	yield (%)[b]	*ee*[c]
1	$Co(OTf)_2$	**L1**	79	6
2	$Co(OTf)_2$	**L2**	68	22
3	$Co(OTf)_2$	**L3**	18	17
4	$Co(OTf)_2$	**L4**	87	1
5	$Co(OTf)_2$	**L5**	73	0
6	$Co(OTf)_2$	**L6**	78	16
7	$Co(OTf)_2$	**L7**	81	13
8	$Co(OTf)_2$	**L8**	77	34
9	$Co(OTf)_2$	**L9**	85	64
10	$Co(OTf)_2$	**L10**	85	70
11	$Fe(OTf)_2$	**L10**	65	88
12	$Ni(OTf)_2$	**L10**	83	28
13	$Sc(OTf)_3$	**L10**	63	0
14	**$Zn(OTf)_2$**	**L10**	**78**	**92**
15[d]	$Zn(OTf)_2$	**L10**	99	88
16[e]	$Zn(OTf)_2$	**L10**	29	86
17[f]	$Zn(OTf)_2$	**L10**	90	51

[a] **1p** (0.1 mmol), **2b** (0.12 mmol), Lewis acid (10 mol%) and ligand (12 mol%) in CH_2Cl_2 (2 mL) at room temperature for 16 h. [b] NMR yield with CH_2Br_2 as an internal standard. [c] Based on chiral HPLC analysis. [d] Performed in 1,4-dioxane. [e] Run at 0 °C. [f] Run at 40 °C.

chiral ligands for the cycloaddition reaction (entries 2-4). The use of **L2** led to an enhancement in enantiomeric excess (22% *ee*, entry 2). Nevertheless, when transitioning to alternative ligands such as **L3**-**L4**, the outcomes were unsatisfactory. The TOX ligand **L4** provided excellent enantioselective control in Tang's (3+3) cycloadditions of cyclopropanes,[4b] but it resulted in racemic **3pb** in the current cycloadditions of BCBs. Recently, Xie and Guo developed two novel tridentate nitrogen ligands, PyBPI and PyIPI, which exhibited effective stereoselective control in Lewis acid catalysis.[28] Thus these ligands were synthesized and evaluated (**L5**-**L10**). While PyBPI **L6** showed poor results in the enantioselective dearomatizing (3+3) reaction, the PyIPI ligand **L10** produced **3pb** with a promising *ee* value (entry 6 *versus* entry 10). After systematically screening various reaction parameters (entries 11-17), we successfully conducted the enantioselective (3+3) reaction using **L10**, resulting in the synthesis of the target compound (*R*)-**3pb** with a 78% NMR yield and 92% *ee* when $Zn(OTf)_2$ was utilized in place of $Co(OTf)_2$.

With the identified reaction conditions D in hand, we examined the scope of this enantioselective (3+3) reaction (Scheme 3). Initially, the variation in BCB was evaluated. BCBs bearing trifluoromethyloxy (**1r**) and trifluoromethyl (**1s**) substituents on the aryl ring, which are popular in pharmaceuticals and agrochemicals, were found to be compatible in the reaction, resulting in the desired product with 95-96% *ee* ((*R*)-**3rb**-**sb**). The presence of halogen substituents at the *para*- or *meta*-position of the benzene ring did not negatively impact the reaction outcome ((*R*)-**3tb**, **3xb** and **3yb**). The *N*-iminoisoquinolinium ylides **2** bearing methoxy, halogen (F, Cl, Br), or methyl groups at the C5-C8 positions of isoquinoline moieties yielded the desired products **3pq**-**3py** with high efficiency and outstanding enantioselectivity.[27] Notably, in some instances, poor yields (<30% NMR yield) of the cycloadducts (**3pr** and **3pw**) under conditions D may be attributed to the low solubility of azomethine imines in CH_2Cl_2. However, high yields (76-81% yield) and stereoselectivity (91-95% *ee*) were successfully attained in CH_2Cl_2/1,4-dioxane (10/1).

To showcase the synthetic utility of these cycloadducts, we initially performed scale-up experiments. Both non-asymmetric and asymmetric systems were successfully scaled up to a 1.0 mmol scale using standard conditions, while preserving efficiency and selectivity. The pyrazole amide group of **3aa** can be easily converted into various valuable functional groups, such as ester (**5**) and carboxylic acid (**7**), smoothly. Primary alcohol **6** and secondary alcohol **9** can be obtained with excellent yield through the $NaBH_4$ reduction of **3aa** and **3ga**, respectively. The reaction of **3ga** with Wittig reagent afforded **8** in 93% yield. Finally, cleavage of the imidazole moiety gave rise to the desired aldehyde **10** in 64% yield and 96% *ee* (Scheme 4).

Control experiments were conducted to gain insight into this asymmetric transformation. When subjecting BCB **1z** to conditions D, we did not observe the rapid decomposition of **1z**, nor did we observe the corresponding side product cyclobutene **11** (Scheme 5A). This result suggests that the benzylic carbocation enolate intermediate may not be involved in the reaction, aligning with the electronic effect observed in BCB substrates. BCBs containing electron-withdrawing groups



Scheme 3. Enantioselective (3+3) cycloadditions of BCBs with azomethine imines.[a,b] [a] Conditions D: **1** (0.2 mmol), **2** (0.24 mmol), $Zn(OTf)_2$ (10 mol%) and **L10** (12 mol%) in CH_2Cl_2 (4 mL) at room temperature for 16 h. [b] Isolated yield. [c] Performed in CH_2Cl_2/1,4-dioxane (10/1, v/v) instead of CH_2Cl_2 for better solubility.



Scheme 4. Scale-up and derivatizations.

(*e.g.*, *p*- and *m*-CF3) on the phenyl ring also yield good results. While BCB **1g** yielded the desired product **3gb** at 9% yield and 0% *ee*, the (3+3) reaction of **1a**, which contains the bidentate chelating group, produced **3ab** with a 6% *ee*. The results indicate that forming a stable chiral environment through the chelation of a bidentate acyl imidazole group on BCB with a Zn-Lewis acid catalyst is essential for achieving enantioselective control. Furthermore, the correlation between the enantiomeric purities of ligands **L10** and (*R*)-**3pb** was assessed. The study uncovered a linear correlation, indicating that the active catalyst/ligand is monomeric in nature (Scheme 5B&C).



Scheme 5. Control experiments and non-linear effect study.

In conclusion, we have established a dearomatizing (3+3) cycloaddition for synthesizing novel diaza-BCHep derivatives from BCBs and aromatic azomethine imines. The good to high overall yields and excellent enantioselectivities are governed by the catalysts and reaction conditions. This straightforward approach operates under mild conditions and exhibits good functional group tolerance. The synthetic utility and practicality were also highlighted by the scale-up experiment and diverse synthetic transformations of the cycloadducts. Notably, this work represents the first Lewis acid-catalyzed asymmetric (3+3) cycloadditions of BCBs, paving the way for the enantioselective synthesis of other valuable bicyclo[n.1.1]alkanes through chiral Lewis acid catalysis.

Acknowledgements

We are grateful to the Fundamental Research Funds for the Central Universities, Natural Science Foundation of Hunan Province (2024JJ6126) and China Postdoctoral Science Foundation (2024M750865) for financial support.

Keywords: Strained Molecules • Cycloadditions • Asymmetric catalysis • Bridged rings • Heterocycles

[1] a) E. Vitaku, D. T. Smith, J. T. Njardarson, *J. Med. Chem.* **2014**, *57,* 10257−10274; b) C. M. Marshall, J. G. Federice, C. N. Bell, P. B. Cox, J. T. Njardarson, *J. Med. Chem.* **2024**, *67*, 11622–11655.

[2] For selected reviews, see: a) J. G. Schantl in *Science of Synthesis*, *Vol. 27* (Eds.: A. Padwa), G. Thieme Verlag KG, Stuttgart, **2004**, pp. 731−738; b) T.-B. Hua, Q.-Q. Yang, W.-J. Xiao, *Chin. J. Org. Chem.* **2020**, *40*, 3559−3595; c) D. Li, X.-C. Chen, W. Gao, *Synthesis* **2020**, *52*, 3337−3355; d) C. Nájera, J. M. Sansano, M. Yus, *Org. Biomol. Chem*. **2015**, *13*, 8596−8636; e) G. Qiu, Y. Kuang, J. Wu, *Adv. Synth. Catal*. **2014**, *356*, 3483−3504; f) X. Xu, M. P. Doyle, *Acc. Chem. Res.* **2014**, *47*, 1396–1405; g) J. J. Mousseau, A. B. Charette, *Acc. Chem. Res.* **2013**, *46*, 412–424.

[3] a) W. Liu, S. Liu, R. Jin, H. Guo, J. Zhao, *Org. Chem. Front*. **2015**, *2*, 288–299; b) J. D. Scott, R. M. William, *Chem. Rev*. **2002**, *102*, 1669−1730.

[4] a) C. Perreault, S. R. Goudreau, L. E. Zimmer, A. B. Charette, *Org. Lett.* **2008**, *10*, 689–692; b) Y.-Y. Zhou, J. Li, L. Ling, S.-H. Liao, X.-L. Sun, Y.-X. Li, L.-J. Wang, Y. Tang, *Angew. Chem. Int. Ed*. **2013**, *52*, 1452–1456.

[5] S. Liao, X.-L. Sun, Y. Tang, *Acc. Chem. Res.* **2014**, *47*, 2260-2272.

[6] a) X. Xu, P. Y. Zavalij, M. P. Doyle, *Angew. Chem. Int. Ed.* **2013**, *52*, 12664–12668. b) K. O. Marichev, F. G. Adly, A. M. Carranco, E. C. Garcia, H. Arman, M. P. Doyle, *ACS Catal.* **2018**, *8*, 10392-10400; c) L. Zhang, H. Liu, G. Qiao, Z. Hou, Y. Liu, Y. Xiao, H. Guo, *J. Am. Chem. Soc.* **2015**, *137*, 4316-4319; d) C. Guo, M. Fleige, D. Janssen-Müller, C. G. Daniliuc, F. Glorius, *Nat. Chem.* **2015**, *7*, 842-847.

[7] a) N. Frank, J. Nugent, B. R. Shire, H. D. Pickford, P. Rabe, A. J. Sterling, T. Zarganes-Tzitzikas, T. Grimes, A. L. Thompson, R. C. Smith, C. J. Schofield, P. E. Brennan, F. Duarte, E. A. Anderson, *Nature* **2022**, *611*, 721−726; b) R. I. Revie, B. J. Whitaker, B. Paul, R. C. Smith, E. A. Anderson, *Org. Lett.* **2024**, *26*, 2843−2846; c) T. Iida, J. Kanazawa, T. Matsunaga, K. Miyamoto, K. Hirano, M. Uchiyama, *J. Am. Chem. Soc.* **2022**, *144*, 21848−21852; d) D. Dibchak, M. Snisarenko, A. Mishuk, O. Shablykin, L. Bortnichuk, O. Klymenko-Ulianov, Y. Kheylik, I. V. Sadkova, H. S. Rzepa, P. K. Mykhailiuk, *Angew. Chem. Int. Ed.* **2023**, e202304246; e) P. K. Mykhailiuk, *Org. Biomol. Chem*. **2019**, *17*, 2839−2849.

[8] Representative examples for synthesis of BCHs, see: a) A. Cairncross, E. P. Blanchard Jr, *J. Am. Chem. Soc.* **1966**, *88*, 496-504; b) P. Wipf, M. A. A. Walczak, *Angew. Chem. Int. Ed.* **2006**, *45*, 4172-4175; c) M. Wang, Y. Huang, C. Li, P. Lu, *Org. Chem. Front.* **2022**, *9*, 2149-2153; d) B. D. Schwartz, A. P. Smyth, P. E. Nashar, M. G. Gardiner, L. R. Malins, *Org. Lett.* **2022**, *24*, 1268-1273; e) R. Kleinmans, T. Pinkert, S. Dutta, T. O. Paulisch, H. Keum, C. G. Daniliuc, F. Glorius, *Nature* **2022**, *605*, 477-482; f) R. Guo, Y.-C. Chang, L. Herter, C. Salome, S. E. Braley, T. C. Fessard, M. K. Brown, *J. Am. Chem. Soc.* **2022**, *144*, 7988-7994; g) Y. Liu, Z. Wu, J.-R. Shan, H. Yan, E.-J. Hao, L. Shi, *Nat. Commun*. **2024**, *15*, 4374; h) S. Agasti, F. Beltran, E. Pye, N. Kaltsoyannis, G. E. M. Crisenza, D. J. Procter, *Nat. Chem.* **2023**, *15*, 535-541; i) H. Ren, T. Li, J. Xing, Z. Li, Y. Zhang, X. Yu, J. Zheng, *Org. Lett.* **2024**, *26*, 1745−1750; j) M. Xu, Z. Wang, Z. Sun, Y. Ouyang, Z. Ding, T. Yu, L. Xu, P. Li, *Angew. Chem. Int. Ed.* **2022**, *61*, e202214507; k) Y. Liu, S. Lin, Y. Li, J.-H. Xue, Q. Li, H. Wang, *ACS Catal.* **2023**, *13*, 5096-5103; l) R. Kleinmans, S. Dutta, K. Ozols, H. Shao, F. Schäfer, R. E. Thielemann, H. T. Chan, C. G. Daniliuc, K. N. Houk, F. Glorius, *J. Am. Chem. Soc.* **2023**, *145*, 12324-12332; m) J. L. Tyler, F. Schäfer, H. Shao, C. Stein, A. Wong, C. G. Daniliuc, K. N. Houk, F. Glorius, *J. Am. Chem. Soc.* **2024**, *146*, 16237–16247; n) Q.-Q. Hu, L.-Y. Wang, X.-H. Chen, Z.-X. Geng, J. Chen, L. Zhou, *Angew. Chem. Int. Ed.* **2024**, *63*, e202405781; o) J.-Y. Su, J. Zhang, Z.-Y. Xin, H. Li, H. Zheng, W.-P. Deng, *Org. Chem. Front.* **2024**, DOI: 10.1039/d4qo00511b; p) J.-J. Wang, L. Tang, Y. Xiao, W.-B. Wu, G. Wang, J.-J. Feng, *Angew. Chem. Int. Ed.* **2024**, *63*, e202405222; q) N. Radhoff, C. G. Daniliuc, A. Studer, *Angew. Chem. Int. Ed.* **2023,** *62*, e202304771; r) D. Ni, S. Hu, X. Tan, Y. Yu, Z. Li, L. Deng, *Angew. Chem. Int. Ed.* **2023**, e202308606; s) M. de Robichon, T. Kratz, F. Beyer, J. Zuber, C. Merten, T. Bach, *J. Am. Chem. Soc.* **2023**, *145*, 24466−24470; t) Q. Fu, S. Cao, J. Wang, X. Lv, H. Wang, X. Zhao, Z. Jiang, J. *Am. Chem. Soc.* **2024**, *146*, 8372−8380; u) M. Reinhold, J. Steinebach, C. Golz, J. C. L. Walker, *Chem. Sci.* **2023**, *14*, 9885−9891; v) L. Yang, H. Wang, M. Lang, J. Wang, S. Peng, *Org. Lett.* **2024**, *26*, 4104−4110; w) K. J. Woelk, K. Dhake, N. D. Schley, D. C. Leitch, *Chem. Commun*. **2023**, *59*, 13847–13850.

[9] a) A. Denisenko, P. Garbuz, N. M. Voloshchuk, Y. Holota, G. Al-Maali, P. Borysko, P. K. Mykhailiuk, *Nat. Chem.* **2023**, *15*, 1155–1163; b) V. V. Levterov, Y. Panasyuk, V. O. Pivnytska, P. K. Mykhailiuk, *Angew. Chem. Int. Ed.* **2020**, *59*, 7161–7167; c) V. V. Levterov, O. Michurin, P. O. Borysko, S. Zozulya, I. V. Sadkova, A. A. Tolmachev, P. K. Mykhailiuk, *J. Org. Chem.* **2018**, *83*, 14350−14361; d) V. V. Levterov, Y. Panasiuk, O. Shablykin, O. Stashkevych, K. Sahun, A. Rassokhin, I, Sadkova, D. Lesyk, A. Anisiforova, Y. Holota, P. Borysko, I. Bodenchuk, N. M. Voloshchuk, P. K. Mykhailiuk, *Angew. Chem. Int. Ed.* **2024,** *63*, e202319831.

[10] For reviews on BCBs, see: a) M. Golfmann, J. C. L. Walker, *Commun. Chem.* **2023**, *6*, 9; b) C. B. Kelly, J. A. Milligan, L. J. Tilley, T. M. Sodano, *Chem. Sci.* **2022**, *13*, 11721-11737; c) A. Fawcett. *Pure Appl. Chem.* **2020**, *92*, 751-765; d) J. Turkowska, J. Durka, D. Gryko, *Chem. Commun.* **2020**, *56*, 5718-5734; e) M. A. A. Walczak, T. Krainz, P. Wipf, *Acc. Chem. Res.* **2015**, *48*, 1149-1158; f) S. J. Sujansky, X. Ma, *Asian J. Org. Chem.* **2024**, e202400045; g) Q.-Q. Hu, J. Chen, Y. Yang, H. Yang, L. Zhou, *Tetrahedron Chem*. **2024**, *9*, 100070. Pioneering examples of catalytic asymmetric ring-openings of BCBs: h) H.-C. Shen, M. V. Popescu, Z.-S. Wang, L. de Lescure, A. Noble, R. S. Paton, V. K. Aggarwal. *J. Am. Chem. Soc.* **2023**, *145*, 16508−16516; i) S.-L. Lin, Y.-H. Chen, H.-H. Liu, S.-H. Xiang, B. Tan, *J. Am. Chem. Soc.* **2023**, *145*, 21152−21158.

[11] Y. Zhang, W. Huang, R. K. Dhungana, A. Granados, S. Keess, M. Makvandi, G. A. Molander, *J. Am. Chem. Soc.* **2022**, *144*, 23685−23690.

[12] T. V. T. Nguyen, A. Bossonnet, M. D. Wodrich, J. Waser, *J. Am. Chem. Soc.* **2023**, *145*, 25411−25421.

[13] T. Yu, J. Yang, Z. Wang, Z. Ding, M. Xu, J. Wen, L. Xu, P. Li, *J. Am. Chem. Soc.* **2023**, *145*, 4304−4310.

[14] Y. Liu, S. Lin, Z. Ding, Y. Li, Y.-J. Tang, J.-H. Xue, Q. Li, P. Li, H. Wang, *ChemRxiv* **2024**, DOI: 10.26434/chemrxiv-2024-n3wlw.

[15] Z. Lin, H. Ren, X. Lin, X. Yu, J. Zheng *J. Am. Chem. Soc.* **2024**, *146*, 18565−18575.

[16] J. Zhang, J.-Y. Su, H. Zheng, H. Li, W.-P. Deng, *Angew. Chem. Int. Ed.* **2024**, *63*, e202318476.

[17] Y. Liang, R. Nematswerani, C. G. Daniliuc, F. Glorius, *Angew. Chem. Int. Ed.* **2024**, *63*, e202402730.

[18] Y. Xiao, F. Wu, L. Tang, X. Zhang, M. Wei, G. Wang, J.-J. Feng, *Angew. Chem. Int. Ed*. **2024**, *63*, e202408578.

[19] J.-L. Zhou, Y. Xiao, L. He, X.-Y. Gao, X.-C. Yang, W.-B. Wu, G. Wang, J. Zhang, J.-J. Feng, *J. Am. Chem. Soc.* **2024**, *146*, 19621−19628.

[20] X. Wang, R. Gao, X. Li, *J. Am. Chem. Soc.* **2024**, *146*, 21069–21077.

[21] a) L. Tang, Y. Xiao, F. Wu, J.-L. Zhou, T.-T. Xu, J.-J. Feng, *Angew. Chem. Int. Ed.* **2023**, *62*, e202310066; b) L. Tang, Q.-N. Huang, F. Wu, Y. Xiao, J.-L. Zhou, T.-T. Xu, W.-B. Wu, S. Qu, J.-J. Feng, *Chem. Sci*. **2023**, *14*, 9696–9703; c) Y. Xiao, T.-T. Xu, J.-L. Zhou, F. Wu, L. Tang, R.-Y. Liu, W.-B. Wu, J.-J. Feng, *Chem. Sci.* **2023**, *14*, 13060–13066.

[22] For groundbreaking research on the Lewis acid-catalyzed cycloadditions of BCBs, see: K. Dhake, K. J. Woelk, J. Becica, A. Un, S. E. Jenny, D. C. Leitch, *Angew. Chem. Int. Ed.* **2022**, *61*, e202204719.

[23] For reviews on dearomatization reactions, see: a) Y.-Z. Cheng, Z. Feng, X. Zhang, S.-L. You, *Chem. Soc. Rev.* **2022**, *51*, 2145-2170; b) C. Zheng, S.-L. You, *ACS Cent. Sci*. **2021**, *7*, 432-444; c) C. J. Huck, D. Sarlah, *Chem* **2020**, *6*, 1589-1603; d) F.-T. Sheng, J.-Y. Wang, W. Tan, Y.-C. Zhang, F. Shi, *Org. Chem. Front.* **2020**, *7*, 3967-3998; e) W. C. Wertjes, E. H. Southgate, D. Sarlah, *Chem. Soc. Rev.* **2018**, *47*, 7996-8017; f) C. Zheng, S.-L. You, *Chem* **2016**, *1*, 830-857; g) R. Remy, C. G. Bochet, *Chem. Rev.* **2016**, *116*, 9816-9849; h) C.-X. Zhuo, C. Zheng, S.-L. You, *Acc. Chem. Res.* **2014**, *47*, 2558-2573; i) Q. Ding, X. Zhou, R. Fan, *Org. Biomol. Chem.* **2014**, *12*, 4807-4815; j) S. P. Roche, J. A. Porco, Jr., *Angew. Chem. Int. Ed.* **2011**, *50*, 4068-4093.

[24] a) K. W. Quasdorf, L. E. Overman, *Nature* **2014**, *516*, 181-191; b) D. Pierrot, I. Marek, *Angew. Chem. Int. Ed.* **2020**, *59*, 36–49; c) S. Kobayashi, Y. Mori, J. S. Fossey, M. M. Salter, *Chem. Rev.* **2011**, *111*, 2626–2704; d) F. Zhou, L. Zhu, B.-W. Pan, Y. Shi, Y.-L. Liu, J. Zhou, *Chem. Sci.* **2020**, *11*, 9341-9365.

[25] Y. Liang, F. Paulus, C. G. Daniliuc, F. Glorius, *Angew. Chem. Int. Ed.* **2023,** *62*, e202305043.

[26] L. Pitzer, F. Schäfers, F. Glorius, *Angew. Chem. Int. Ed.* **2019**, *58*, 8572 –8576.

[27] Deposition numbers 2375376 (for **3po**) and 2375377 (for (*R*)-**3pv**) contain the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service.

[28] a) X.-B. Wang, Y. Tian, L. Zhou, M.-S. Xie, G.-R. Qu, H.-M. Guo, *Org. Lett.* **2022**, *24*, 386−3866; b) B.-Y. Xue, C.-Y. Hou, X.-B. Wang, M.-S. Xie, H.-M. Guo, *Org. Chem. Front.* **2023**, *10*, 1910-1914; c) H.-X. Wang, C. Yang, B.-Y. Xue, M.-S. Xie, Y. Tian, C. Peng, H.-M. Guo, *Nat. Commun.* **2023**, *14*, 2270; d) X.-Y. Wang, X.-B. Wang, Y. Tian, C. Peng, M.-S. Xie, H.-M. Guo, *ACS Catal.* **2023**, *13*, 11528−11540.

Entry for the Table of Contents



A strategy for the dearomatizing (3+3) cycloadditions of bicyclobutanes with *N*-iminoquinolinium and *N*-iminoisoquinolinium ylides is presented. The method enables the expansion of the chemical space of diazabicyclo[3.1.1]heptanes. In particular, The Lewis acid-catalyzed asymmetric approach is introduced, paving the way for the enantioselective synthesis of other valuable bicyclo[n.1.1]alkanes using chiral Lewis acid catalysis.